Phase II open label study of valproic acid in spinal muscular atrophy

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Swoboda, Kathryn J ^a   Scott, Charles B ^b   Reyna, Sandra P ^a   Prior, Thomas W ^c   LaSalle, Bernard ^a   Sorenson, Susan L ^a   Wood, Janine ^a   Acsadi, Gyula ^d   Crawford, Thomas O ^e   Kissel, John T ^c   Krosschell, Kristin J ^f   D'Anjou, Guy ^g   Bromberg, Mark B ^a   Schroth, Mary K ^h   Chan, Gary M ^a   Elsheikh, Bakri ^c   Simard, Louise R ⁱ  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CBS   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF MONTREAL   (Canada)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; MESSENGER RNA; VALPROATE SEMISODIUM; ENZYME INHIBITOR; SMN2 PROTEIN, HUMAN; SURVIVAL MOTOR NEURON PROTEIN 2; VALPROIC ACID;

ABNORMAL LABORATORY RESULT; ACIDOSIS; ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD LEVEL; BODY COMPOSITION; BODY MASS; BONE DENSITY; CARNITINE DEFICIENCY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FORCED EXPIRATORY VOLUME; HAMMERSMITH FUNCTIONAL MOTOR SCALE; HUMAN; LEUKOPENIA; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MOOD CHANGE; MOTOR PERFORMANCE; MOTOR UNIT; MUSCLE ACTION POTENTIAL; MUSCLE INNERVATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; RATING SCALE; RESPIRATORY FAILURE; SIDE EFFECT; SPINAL MUSCULAR ATROPHY; WEAKNESS; WEIGHT GAIN; ANALYSIS OF VARIANCE; DRUG EFFECT; ELECTROPHYSIOLOGY; GENETICS; NEUROLOGIC EXAMINATION; PATHOLOGY; PHOTON ABSORPTIOMETRY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BODY COMPOSITION; BONE DENSITY; CHILD; CHILD, PRESCHOOL; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; HUMANS; MUSCULAR ATROPHY, SPINAL; NEUROLOGIC EXAMINATION; RESPIRATORY FUNCTION TESTS; SURVIVAL OF MOTOR NEURON 2 PROTEIN; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 65849222556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005268     Document Type: Article

References (45)

1. Brahe C, Bertini E (1996) Spinal muscular atrophies: recent insights and impact on molecular diagnosis. J Mol Med 74: 555-562.
2. Roberts DF, Chavez J, Court SD (1970) The genetic component in child mortality. Arch Dis Child 45: 33-38.
3. Pearn J (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15: 409-413.
4. Czeizel A, Hamula J (1989) A hungarian study on Werdnig-Hoffmann disease. J Med Genet 26: 761-763.
5. Emery AE (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1: 19-29.
6. Merlini L, Stagni SB, Marri E, Granata C (1992) Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy. Neuromuscul Disord 2: 197-200.
7. Lefebvre S, Burgien L, Reboullet S, Clermont O, Burlet P, et al. (1995) Identification and Characterization of a Spinal Muscular Atrophy-determining Gene. Cell 80: 155-165.
8. Wan L, Battle DJ, Yong J, Gubitz AK, Kolb SJ, et al. (1995) The Survival of Motor Neurons Protein Determines the Capacity for snRNP Assembly: Biochemical Deficiency in Spinal Muscular Atrophy. Mol Cell Biol 25(13): 5543-51.
9. Lorson CL, Hahnen E, Androphy EJ, Wirth B (1998) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96: 6307-6311.
10. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular Atrophy (2002) Am J Hum Genet. 70(2): 358-368.
11. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, et al. (2002) Molecular Analysis of Spinal Muscular Atrophy and Modification of the Phenotype by SMN2. Genet Med 4: 20-26.
12. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, et al. (2005) Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57: 704-712.
13. Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, et al. (2006) Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet 119: 422-428.
14. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ (2004) Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A 130: 307-310.
15. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, et al. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269.
16. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98: 9808-9813.
17. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, et al. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489.
18. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54: 647-654.
19. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12: 59-65.
20. Grzeschik SM, Ganta M, Prior TW, Heavlin WD, Wang CH (2005) Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58: 194-202.
21. Brichta L, Holker I, Haug K, Klockgether T, Wirth B (2006) In Vivo Activation of SMN in Spinal Muscular Atrophy Carriers and Patients Treated with Valproate. Ann Neurol 59: 970-975.
22. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, et al. (2005) Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 13: 256-259.
23. Kernochan LE, Russo ML, Woodling NS, Huynh TN, Avila AM, et al. (2005) The role of histone acetylation in SMN gene expression. Hum Mol Genet 14: 1171-1182.
24. Leng Y, Chuang DM (2006) Endogenous α-Synuclein is Induced by Valproic Acid through Histone Deacetylase Inhibition and Participates in Neuroprotection against Glutamate-Induced Excitotoxicity. J Neurosci 26(28): 7502-7512.
25. van Bergeijk J, Haastert K, Grothe C, Claus P (2006) Valproic acid promotes neurite outgrowth in PC12 cells independent from regulation of the survival of motoneuron protein. Chem Biol Drug Des 67: 244-247.
26. Sugai F, Yamamoto Y, Miyaguchi K, Zhou Z, Sumi H, et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179-3183.
27. Petri S, Kiaei M, Kipiani K, Chen J, Chalingasan NY, et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40-49.
28. Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H (2006) Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis 24: 286-295.
29. Tsai LK, Tsai MS, Ting CH, Li H (2008) Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 86: 1243-1254.
30. Weihl CC, Connolly AM, Pestronk A (2006) Valproate may improve strength and function in patients with type III/IV spinal muscular atrophy. Neurology 67: 500-501.
31. Tsai LK, Yang CC, Hwu WL, Li H (2007) Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol 14: e8-e9.
32. Main M, Kairon K, Mercuri E, Muntoni F (2003) The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 7: 155-159.
33. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ (2006) A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 16: 417-426.
34. Mercuri E, Messina S, Battini R, Berrardinelli A, Boffi P, et al. (2006) Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a Multicentric Study. Neuromuscul Disord 16: 93-98.
35. Bromberg MB, Swoboda KJ (2002) Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 25: 445-447.
36. Simard LR, Belanger M-C, Morrissette S, Wride M, Prior TW, et al. (2007) Preclinical validation of a multiplex real-time RT-PCR assay to quantify SMN transcripts in whole blood from SMA patients. Neurology 68: 451-456.
37. Sumner CJ, Kolb SJ, Harmison GG, Jeffries NO, Schadt K, et al. (2006) SMN mRNA and protein levels in peripheral blood. Neurology 66: 1067-1073.
38. Melegh B, Pap M, Morava E, Molnar D, Dani M, et al. (1994) Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr 125: 317-321.
39. Tein I, Sloane AE, Donner EJ, Lehotay DC, Millington DS, et al. (1995) Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr Neurol 12: 21-30.
40. Crawford TO, Sladky JT, Hurko O, Besner-Johnston A, Kelley RI (1999) Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol 45: 337-343.
41. Coulter DL (1984) Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1(8378): 689.
42. Kumandas S, Koklu E, Gümüs H, Koklu S, Kurtoglu S, et al. (2006) Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 19: 529-534.
43. Boluk A, Guzelipek M, Savli H, Temel I, Iin Oziik H, et al. (2004) The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50: 93-97.
44. Ecevit C, Aydoǧan A, Kavakli T, Altinöz S (2004) Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 31: 279-282.
45. Leet AI, Mesfin A, Pichard C, Launay F, Brintzenhofeszoc K, et al. (2006) Fractures in children with cerebral palsy. J Pediatr Orthop 26: 624-627.